Download MendeleyBMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity.
Bae, S.H., Kim, J.H., Park, T.H., Lee, K., Lee, B.I., Jang, H.(2022) Exp Mol Med 54: 1450-1460
- PubMed: 36056187
- DOI: https://doi.org/10.1038/s12276-022-00840-x
- Primary Citation of Related Structures:
7XHY - PubMed Abstract:
Myeloid epithelial reproductive proto-oncogene tyrosine kinase (MERTK) plays an essential role in modulating cancer immune tolerance by regulating macrophage efferocytosis. Studies are underway to develop small-molecule chemicals that inhibit MERTK as cancer immunotherapeutic agents, but these efforts are in their early stages. This study identified BMS794833, whose primary targets are MET and VEGFR2, as a potent MERTK inhibitor and developed a real-time efferocytosis monitoring system. The X-ray cocrystal structure revealed that BMS794833 was in contact with the ATP-binding pocket and the allosteric back pocket, rendering MERTK inactive. Homogeneous time-resolved fluorescence kinetic and Western blotting analyses showed that BMS794833 competitively inhibited MERTK activity in vitro and inhibited the autophosphorylation of MERTK in macrophages. We developed a system to monitor MERTK-dependent efferocytosis in real time, and using this system, we confirmed that BMS794833 significantly inhibited the efferocytosis of differentiated macrophages. Finally, BMS794833 significantly inhibited efferocytosis in vivo in a mouse model. These data show that BMS794833 is a type II MERTK inhibitor that regulates macrophage efferocytosis. In addition, the real-time efferocytosis monitoring technology developed in this study has great potential for future applications.
Organizational Affiliation:
Reasearch Institute, National Cancer Center, Goyang, 10408, Republic of Korea.
